04:39 PM EDT, 04/08/2025 (MT Newswires) -- NeOnc Technologies ( NTHI ) said Tuesday that its phase 1 trial of NEO212 for the treatment of brain cancer is nearing full enrollment.

The final group is expected to complete the study's dosing protocol, the company said, adding that the NEO212 trial protocol has five escalating groups with three patients per group.

NEO212 is a combination of temozolomide, which is the current standard-of-care chemotherapy for malignant gliomas, and perillyl alcohol, NeOnc ( NTHI ) said.